Dengue Vaccine Name and Administration Protocol
The recommended dengue vaccine in the United States is Dengvaxia (CYD-TDV), administered as a 3-dose series (0.5 mL subcutaneously at 0,6, and 12 months) for children aged 9-16 years who have laboratory-confirmed previous dengue infection and live in endemic areas. 1
Vaccine Eligibility Requirements
Critical Pre-Vaccination Requirement
- Laboratory confirmation of prior dengue infection is mandatory before vaccination 1
- Use a highly specific serodiagnostic test to detect anti-DENV immunoglobulin G
- This requirement exists because Dengvaxia increases the risk of severe dengue in seronegative individuals experiencing their first natural infection after vaccination 1
Age and Geographic Criteria
- Age range: 9-16 years only 1
- Geographic requirement: Must reside in U.S. endemic areas including:
- Puerto Rico
- American Samoa
- U.S. Virgin Islands
- Federated States of Micronesia
- Republic of Marshall Islands
- Republic of Palau 1
Administration Schedule
Three-dose series:
- Dose 1: Initial dose (0.5 mL subcutaneous)
- Dose 2: 6 months after first dose
- Dose 3: 12 months after first dose 1
Important Clinical Considerations
Contraindications
- Seronegative individuals (no prior dengue infection)
- Immunocompromised patients (live-attenuated vaccine) 2
- Pregnant women 2
Recent Updates (2025)
The 2025 ACIP immunization schedule clarifies that dengue vaccination is recommended for "certain high-risk groups or populations" within the 9-16 year age range 3. The schedule specifically designates this as a purple-coded recommendation, indicating targeted use rather than universal vaccination.
Alternative Vaccine (Not FDA-Approved in U.S.)
Qdenga® (TAK-003) is available in other countries and recommended for children aged 6-16 years in high-transmission areas, with some international guidelines suggesting extension to at-risk adults 4, 2. However, this vaccine is not currently approved for use in the United States.
Common Pitfall to Avoid
Never vaccinate without serological confirmation of prior dengue infection. The risk of antibody-dependent enhancement (ADE) in dengue-naive individuals makes pre-vaccination testing non-negotiable 1. This represents a unique requirement among routine vaccines and must be strictly followed to prevent increased risk of severe disease.